We noticed that studies linked to a statistically significant favourable prognosis in OS [35, 37], restricted the multivariate analysis to a sub-set of ovarian cancer patients with advanced stage, serous histotype, and poor differentiated tumours (Table 2): this way, the positivity for p53-AAs increased from 24% to 30% [35] and from 32% to 42% [37]. This evidence concerns the gene TP53 and ovarian carcinoma.